Download PDF
Thromb Haemost 1991; 66(05): 534-539
DOI: 10.1055/s-0038-1646455
Original Article
Schattauer GmbH Stuttgart

Lipoprotein Associated Coagulation Inhibitor, Factor VII, Antithrombin III, and Monocyte Tissue Factor Following Surgery

Steven D Carson
*   The Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA
,
William D Haire
+   The Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
,
George J Broze Jr.
#   The Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO, USA
,
William F Novotny
#   The Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO, USA
,
Samuel J Pirrucello
*   The Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA
,
Michael J Duggan
*   The Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA
› Author Affiliations
Further Information

Publication History

Received 11 December 1990

Accepted 24 April 1991

Publication Date:
25 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Fifteen patients undergoing major surgical procedures were evaluated for lipoprotein associated coagulation inhibitor (LACI) antigen, factor VII (F VII), antithrombin III (AT III), and peripheral blood monocyte tissue factor (TF) activity immediately before surgery and on following days. A peak in monocyte TF activity occurred between the first and fifth days after surgery in 10 of the patients, while LACI, F VII, and AT III levels dropped in a qualitatively parallel manner in 8 of these patients. LACI, F VII, and AT III levels decreased after surgery in two additional patients even though TF activity also decreased after surgery in these patients. In the remaining 3 patients who developed infections during the study, TF activity rose within 2 days of the diagnosis of infection in addition to the postoperative peak. In two of these patients, LACI levels increased dramatically near the end of the study period without concomitant changes in F VII and AT III. Overall, the presurgical TF levels in disrupted monocytes varied 52-fold and the maximal TF activity varied 24-fold among patients. The TF response following surgery is therefore heterogenous in both temporal occurrence and magnitude of the postsurgical peak. The patients also varied considerably in the presurgical levels of monocyte TF activity. A possible association between the level of presurgical TF activity and the magnitude of the postsurgical peak was noted. Thirteen of the patients had malignant disease, and, as a group, had presurgical levels of LACI (83 ± 26; mean ± SD), F VII (124 ± 22) and AT III (111 ± 14) within the normal ranges established with pooled reference plasma and similar values for three normal donors studied over the same period (AT III 121 ± 6, LACI 95 ± 4, and F VII 112 ± 29). No cause-effect relationship could be established between changes in TF activity and changes in the other factors measured. Patient- or therapy-specific variables may determine postoperative variations in LACI, F VII, AT III, and monocyte TF.

 

  • References

  • 1 Watzke I, Watzke H. Thromboembolic risk factors in patients undergoing maxillofacial surgery for malignancies. Oral Surg Oral Med Oral Pathol 1989; 67: 137-40
    CrossrefPubMedGoogle Scholar
  • 2 Anderson TR, Berner NS, Larsen ML, Odegaard OR, Abildgaard U. Plasma heparin cofactor II, protein C and antithrombin in elective surgery. Acta Chir Scand 1987; 153: 294-6
    PubMedGoogle Scholar
  • 3 Sandset PM, Hogevold HE, Lyberg T, Andersson TR, Abildgaard U. Extrinsic pathway inhibitor in elective surgery: a comparison with other coagulation inhibitors. Thromb Haemostas 1989; 62: 856-60
    PubMedGoogle Scholar
  • 4 Osterud B, Due Jr J. Blood coagulation in patients with benign and malignant tumours before and after surgery. Special reference to thromboplastin generation in monocytes. Scand J Haematol 1984; 32: 258-64
    CrossrefPubMedGoogle Scholar
  • 5 Eriksson BI, Eriksson E, Gyzander E, Teger-Nilsson AC, Risberg B. Thrombosis after hip replacement. Relationship to the fibrinolytic system. Acta Orthop Scand 1989; 6: 159-63
    PubMedGoogle Scholar
  • 6 Nygaard OP, Unneberg K, Reikeras O, Osterud B. Thromboplastin activity of blood monocytes after total hip replacement. Scand J Clin Lab Invest 1990; 50: 183-6
    CrossrefPubMedGoogle Scholar
  • 7 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8
    PubMedGoogle Scholar
  • 8 Bach R. Initiation of coagulation by tissue factor. CRC Crit Rev Biochem 1988; 23: 339-68
    PubMedGoogle Scholar
  • 9 Carson SD. Tissue factor-initiated coagulation. Prog Clin Pathol 1984; 9: 1-14
    PubMedGoogle Scholar
  • 10 Pitlick FA, Nemerson Y. Purification and characterization of tissue factor apoprotein. Methods Enzymol 1976; 45: 37-48
    PubMedGoogle Scholar
  • 11 Zur M, Nemerson Y. Radiometric assays for blood coagulation factors. Methods Enzymol 1981; 80: 237-49
    PubMedGoogle Scholar
  • 12 Carson SD. Computerized analysis of enzyme cascade reactions using continuous rate data obtained with an ELISA reader. Comput Programs Biomed 1985; 19: 151-7
    CrossrefPubMedGoogle Scholar
  • 13 Carson SD, Bach R, Carson SM. Monoclonal antibodies against bovine tissue factor which block interaction with factor VIIa. Blood 1985; 66: 152-6
    PubMedGoogle Scholar
  • 14 Carson SD, Ross SE, Bach R, Guha A. An inhibitory monoclonal antibody against human tissue factor. Blood 1987; 70: 490-3
    PubMedGoogle Scholar
  • 15 Morrissey JH, Fair DS, Edgington TS. Monoclonal antibody analysis of purified and cell-associated tissue factor. Thromb Res 1988; 52: 247-61
    CrossrefPubMedGoogle Scholar
  • 16 Broze Jr GJ, Girard TJ, Novotny WF. Perspectives in Biochemistry: Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-46
    CrossrefPubMedGoogle Scholar
  • 17 Rapaport SI. Inhibition of factor VIIa/tissue factor-induced blood coagulation with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood 1989; 73: 359-65
    PubMedGoogle Scholar
  • 18 Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard TJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988; 71: 335-43
    PubMedGoogle Scholar
  • 19 Blakowski SA, Zacharski LR, Beck JR. Postoperative elevation of human peripheral blood monocyte tissue factor coagulant activity. J Lab Clin Med 1986; 108: 117-20
    PubMedGoogle Scholar
  • 20 Warr TA, Warn-Cramer BJ, Rao LV, Rapaport SI. Human plasma extrinsic pathway inhibitor activity. I. standardization of assay and evaluation of physiologic variables. Blood 1989; 74: 201-6
    PubMedGoogle Scholar
  • 21 Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze Jr GJ. Plasma LACI antigen in patient samples. Blood 1991; 78: 387-393
    PubMedGoogle Scholar
  • 22 Carson SD, Pirruccello SJ, Haire WD. Tissue factor antigen and activity are not expressed on the surface of intact cells in an acute promyelocytic leukemia. Thromb Res 1990; 59: 159-70
    CrossrefPubMedGoogle Scholar
  • 23 Carson SD. Continuous chromogenic tissue factor assay: Comparison to clot-based assays and sensitivity established using pure tissue factor. Thromb Res 1978; 47: 379-87
    PubMedGoogle Scholar
  • 24 Miletich JP, Broze Jr GJ, Majerus PW. Purification of human coagulation factors II, IX, and X using sulfated dextran beads. Methods Enzymol 1981; 80: 221-8
    PubMedGoogle Scholar
  • 25 Broze Jr GJ, Leykam JE, Schwartz BD, Miletich JP. Purification of human brain tissue factor. J Biol Chem 1985; 260: 10917-20
    PubMedGoogle Scholar
  • 26 Carson SD, Archer PG. Tissue factor activity in HeLa cells measured with a continuous chromogenic assay and ELISA reader. Thromb Res 1986; 41: 185-95
    CrossrefPubMedGoogle Scholar
  • 27 Giddings JC. Hereditary coagulation disorders: Laboratory techniques. In: Blood Coagulation and Haemostasis.. Thomson JM. (ed) Livingstone-Churchill, Edingburgh: 1990. pp 136-7
    Google Scholar
  • 28 Holmes EW, Fareed J, Bermes Jr EW. Automation of plasma antithrombin III assays. Clin Chem 1981; 27: 816-8
    PubMedGoogle Scholar
  • 29 Rosenberg RD. Biochemistry of heparin antithrombin interactions, and the physiological role of this natural anticoagulant mechanism. Am J Med 1989; 8 7(Suppl. 3B) 25-95
    PubMedGoogle Scholar
  • 30 Dvorak HE. Abnormalities of hemostasis in malignancy. In: Hemostasis and Thrombosis.. Colman RW, Hirsch J, Marder VJ, Salzman EW. (eds) JB Lippincott Co, Philadelphia, PA: 1987. pp 1143-57
    Google Scholar
  • 31 Donati MB, Davidson JF, Garattini S. (eds) Malignancy and the Hemostatic System. Raven Press, New York: 1981
    Google Scholar
  • 32 Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62: 14-31
    PubMedGoogle Scholar